Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease
NCT05466422Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2022
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mk-2214 in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (5 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced an Adverse Event at 297 days, Number of Participants Who Discontinued Study Treatment Due to an AE at 57 days and 9 more. Started Sep 2022; status: completed.
02
Drugs
mk-2214
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT05466422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05466422.